Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its cancer drug Keytruda expires in two years. Merck received accelerated approval for Keytruda from the...

Redirecting to full article...